<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33809456</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Molecular Alterations in Sporadic and <i>SOD1</i>-ALS Immortalized Lymphocytes: Towards a Personalized Therapy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3007</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22063007</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurological condition where motor neurons (MNs) degenerate. Most of the ALS cases are sporadic (sALS), whereas 10% are hereditarily transmitted (fALS), among which mutations are found in the gene that codes for the enzyme superoxide dismutase 1 (SOD1). A central question in ALS field is whether causative mutations display selective alterations not found in sALS patients, or they converge on shared molecular pathways. To identify specific and common mechanisms for designing appropriate therapeutic interventions, we focused on the <i>SOD1</i>-mutated (<i>SOD1</i>-ALS) versus sALS patients. Since ALS pathology involves different cell types other than MNs, we generated lymphoblastoid cell lines (LCLs) from sALS and <i>SOD1</i>-ALS patients and healthy donors and investigated whether they show changes in oxidative stress, mitochondrial dysfunction, metabolic disturbances, the antioxidant NRF2 pathway, inflammatory profile, and autophagic flux. Both oxidative phosphorylation and glycolysis appear to be upregulated in lymphoblasts from sALS and <i>SOD1</i>-ALS. Our results indicate significant differences in NRF2/ARE pathway between sALS and <i>SOD1</i>-ALS lymphoblasts. Furthermore, levels of inflammatory cytokines and autophagic flux discriminate between sALS and <i>SOD1</i>-ALS lymphoblasts. Overall, different molecular mechanisms are involved in sALS and <i>SOD1</i>-ALS patients and thus, personalized medicine should be developed for each case.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lastres-Becker</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4968-2175</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas "Alberto Sols" UAM-CSIC, Arturo Duperier 4, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Arturo Duperier 4, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute Te&#xf3;filo Hernando for Drug Discovery, Universidad Aut&#xf3;noma de Madrid, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Gracia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Avd, Ramiro Maetzu 9, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arribas-Bl&#xe1;zquez</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas "Alberto Sols" UAM-CSIC, Arturo Duperier 4, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Arturo Duperier 4, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maestro</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Avd, Ramiro Maetzu 9, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrego-Hern&#xe1;ndez</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ALS Unit, Hospital 12 de Octubre Research Institute (i+12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boya</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3045-951X</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Avd, Ramiro Maetzu 9, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerd&#xe1;n</LastName><ForeName>Sebasti&#xe1;n</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas "Alberto Sols" UAM-CSIC, Arturo Duperier 4, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Redondo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7646-386X</Identifier><AffiliationInfo><Affiliation>ALS Unit, Hospital 12 de Octubre Research Institute (i+12), 28041 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2707-8110</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Avd, Ramiro Maetzu 9, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Requero</LastName><ForeName>&#xc1;ngeles</ForeName><Initials>&#xc1;</Initials><Identifier Source="ORCID">0000-0002-3416-9440</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas-CSIC, Avd, Ramiro Maetzu 9, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>B2017/BMD-3813</GrantID><Agency>Comunidad de Madrid</Agency><Country/></Grant><Grant><GrantID>PID2019-105600RB-I00</GrantID><Agency>Agencia Estatal de Investigaci&#xf3;n</Agency><Country/></Grant><Grant><GrantID>MSCA-ITN-ETN (grant DRIVE GA: 765912</GrantID><Agency>H2020 Marie Sk&#x142;odowska-Curie Actions</Agency><Country/></Grant><Grant><GrantID>2019/00325/001</GrantID><Agency>Fundela</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000143">Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017392">Thiobarbituric Acid Reactive Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000143" MajorTopicYN="N">Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017392" MajorTopicYN="N">Thiobarbituric Acid Reactive Substances</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NRF2</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">bioenergetic metabolism</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">lymphoblast</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>3</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33809456</ArticleId><ArticleId IdType="pmc">PMC8000750</ArticleId><ArticleId IdType="doi">10.3390/ijms22063007</ArticleId><ArticleId IdType="pii">ijms22063007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Cheng X., Zhong S., Zhang X., Liu C., Liu F., Zhao C. Peripheral and central nervous system immune response crosstalk in amyotrophic lateral sclerosis. Front. Neurosci. 2020;14:575. doi: 10.3389/fnins.2020.00575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00575</ArticleId><ArticleId IdType="pmc">PMC7308438</ArticleId><ArticleId IdType="pubmed">32612503</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J., Arozamena S., De Muna&#xed;n A.L. Dermic-derived fibroblasts for the study of amyotrophic lateral sclerosis. Neural Regen. Res. 2020;15:2043&#x2013;2044. doi: 10.4103/1673-5374.282257.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.282257</ArticleId><ArticleId IdType="pmc">PMC7716046</ArticleId><ArticleId IdType="pubmed">32394958</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G., Lupino E., Calvo A., Moglia C., Buccinn&#xe0; B., Grifoni S., Ramondetti C., Lomartire A., Rinaudo M.T., Piccinini M., et al. Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathol. 2011;121:611&#x2013;622. doi: 10.1007/s00401-010-0786-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0786-7</ArticleId><ArticleId IdType="pubmed">21120508</ArticleId></ArticleIdList></Reference><Reference><Citation>Posa D., Mart&#xed;nez-Gonz&#xe1;lez L., Bartolom&#xe9; F., Nagaraj S., Porras G., Mart&#xed;nez A., Mart&#xed;n-Requero &#xc1;. Re-capitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients. Mol. Neurobiol. 2019;56:2424&#x2013;2432. doi: 10.1007/s12035-018-1249-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1249-8</ArticleId><ArticleId IdType="pubmed">30030753</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolom&#xe9; F., Mu&#xf1;oz U., Esteras N., Esteban J., Bermejo-Pareja F., Mart&#xed;n-Requero A. Distinct regulation of cell cycle and survival in lymphocytes from patients with Alzheimer&#x2019;s disease and amyotrophic lateral sclerosis. Int. J. Clin. Exp. Pathol. 2009;2:390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615596</ArticleId><ArticleId IdType="pubmed">19158936</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C., Leoni E., Milani P., Pansarasa O., Mazzini G., Guareschi S., Alvisi E., Ghiroldi A., Diamanti L., Bernuzzi S., et al. Altered intracellular localization of SOD1 in leukocytes from patients with sporadic amyotrophic lateral sclerosis. PLoS ONE. 2013;8:e75916. doi: 10.1371/journal.pone.0075916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075916</ArticleId><ArticleId IdType="pmc">PMC3796534</ArticleId><ArticleId IdType="pubmed">24155874</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Pozzi S., Pignataro M., Lauranzano E., Spano G., Garbelli S., Mantovani S., Marinou K., Papetti L., Monteforte M., et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS ONE. 2011;6:e25545. doi: 10.1371/journal.pone.0025545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025545</ArticleId><ArticleId IdType="pmc">PMC3187793</ArticleId><ArticleId IdType="pubmed">21998667</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O., Bordoni M., Drufuca L., Diamanti L., Sproviero D., Trotti R., Bernuzzi S., La Salvia S., Gagliardi S., Ceroni M., et al. Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms. Dis. Model. Mech. 2018;11:dmm031625. doi: 10.1242/dmm.031625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.031625</ArticleId><ArticleId IdType="pmc">PMC5897724</ArticleId><ArticleId IdType="pubmed">29419416</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Gonz&#xe1;lez L., Rodr&#xed;guez-Cueto C., Cabezudo D., Bartolom&#xe9; F., Andr&#xe9;s-Benito P., Ferrer I., Gil C., Mart&#xed;n-Requero &#xc1;., Fern&#xe1;ndez-Ruiz J., Mart&#xed;nez A., et al. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1&#x3b4; kinase inhibitor treatment. Sci. Rep. 2020;10:1&#x2013;12. doi: 10.1038/s41598-020-61265-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61265-y</ArticleId><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="pubmed">32157143</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaca G., Martinez-Gonzalez L., Fernandez A., Rojas-Prats E., Porras G., Cuevas E.P., Gil C., Martinez A., Martin-Requero &#xc1;. Therapeutic potential of novel cell division cycle kinase 7 inhibitors on TDP-43-related pathogenesis such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) J. Neurochem. 2021;156:379&#x2013;390. doi: 10.1111/jnc.15118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15118</ArticleId><ArticleId IdType="pubmed">32628315</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz U., Bartolom&#xe9; F., Bermejo F., Mart&#xed;n-Requero A. Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer&#x2019;s dementia patients. Neurobiol. Aging. 2008;29:1474&#x2013;1484. doi: 10.1016/j.neurobiolaging.2007.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.03.013</ArticleId><ArticleId IdType="pubmed">17448572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolom&#xe9; F., de Las Cuevas N., Mu&#xf1;oz U., Bermejo F., Mart&#xed;n-Requero A. Impaired apoptosis in lymphoblasts from Alzheimer&#x2019;s disease patients: Cross-talk of Ca2+/calmodulin and ERK1/2 signaling pathways. Cell. Mol. Life Sci. 2007;64:1437&#x2013;1448. doi: 10.1007/s00018-007-7081-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-007-7081-3</ArticleId><ArticleId IdType="pubmed">17502994</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS clinical trials review: 20 Years of failure. Are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N., Agosta F., Lunetta C., Filippi M., Quattrini A. Recent advances in amyotrophic lateral sclerosis. J. Neurol. 2016;263:1241&#x2013;1254. doi: 10.1007/s00415-016-8091-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8091-6</ArticleId><ArticleId IdType="pmc">PMC4893385</ArticleId><ArticleId IdType="pubmed">27025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor P.J., Brown H.R., Cleveland W.D. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Krishna Chaitanya R., Preedy V.R. Chapter 20&#x2014;Assessment of antioxidant potential of dietary components. In: Preedy V.R., Watson R.R., editors. HIV/AIDS. Academic Press; Cambridge, MA, USA: 2018. pp. 239&#x2013;253.</Citation></Reference><Reference><Citation>Baird L., Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell. Biol. 2020;40:e00099-20. doi: 10.1128/MCB.00099-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00099-20</ArticleId><ArticleId IdType="pmc">PMC7296212</ArticleId><ArticleId IdType="pubmed">32284348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Lu Y., Qi F., Su Q., Wang L., You C., Che F., Yu J. Effect of the human SOD1-G93A gene on the Nrf2/ARE signaling pathway in NSC-34 cells. Mol. Med. Rep. 2014;9:2453&#x2013;2458. doi: 10.3892/mmr.2014.2087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2087</ArticleId><ArticleId IdType="pubmed">24682253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Front. Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen M.N., Wuolikainen A., Nilsson A.C., Wirenfeldt M., Forsberg K., Madsen J.S., Lillevang S.T., Brandslund I., Andersen P.M., Asgari N. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e697. doi: 10.1212/NXI.0000000000000697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000697</ArticleId><ArticleId IdType="pmc">PMC7136052</ArticleId><ArticleId IdType="pubmed">32123048</ArticleId></ArticleIdList></Reference><Reference><Citation>Amsen D., de Visser K.E., Town T. Approaches to determine expression of inflammatory cytokines. Methods Mol. Biol. 2009;511:107&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698024</ArticleId><ArticleId IdType="pubmed">19347295</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Kaplan V., Livneh I., Avni N., Fabre B., Ziv T., Kwon Y.T., Ciechanover A. p62- and ubiquitin-dependent stress-induced autophagy of the mammalian 26S proteasome. Proc. Natl. Acad. Sci. USA. 2016;113:E7490&#x2013;E7499. doi: 10.1073/pnas.1615455113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1615455113</ArticleId><ArticleId IdType="pmc">PMC5127335</ArticleId><ArticleId IdType="pubmed">27791183</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky D.J., Abdelmohsen K., Abe A., Abedin M.J., Abeliovich H., Acevedo Arozena A., Adachi H., Adams C.M., Adams P.D., Adeli K., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016;12:1&#x2013;222. doi: 10.1080/15548627.2015.1100356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2015.1100356</ArticleId><ArticleId IdType="pmc">PMC4835977</ArticleId><ArticleId IdType="pubmed">26799652</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Shaw P.J. Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Su L.-J., Zhang J.-H., Gomez H., Murugan R., Hong X., Xu D., Jiang F., Peng Z.-Y. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid. Med. Cell. Longev. 2019;2019:5080843. doi: 10.1155/2019/5080843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5080843</ArticleId><ArticleId IdType="pmc">PMC6815535</ArticleId><ArticleId IdType="pubmed">31737171</ArticleId></ArticleIdList></Reference><Reference><Citation>Que X., Hung M.Y., Yeang C., Gonen A., Prohaska T.A., Sun X., Diehl C., M&#xe4;&#xe4;tt&#xe4; A., Gaddis D.E., Bowden K., et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018;558:301&#x2013;306. doi: 10.1038/s41586-018-0198-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0198-8</ArticleId><ArticleId IdType="pmc">PMC6033669</ArticleId><ArticleId IdType="pubmed">29875409</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C., Kawamata H., Bredvik K.G., Arreguin A.J., Cajamarca S.A., Hupf J.C., Ravits J.M., Miller T.M., Maragakis N.J., Hales C.M., et al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol. Neurodegener. 2017;12:76. doi: 10.1186/s13024-017-0217-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0217-5</ArticleId><ArticleId IdType="pmc">PMC5655870</ArticleId><ArticleId IdType="pubmed">29065921</ArticleId></ArticleIdList></Reference><Reference><Citation>Vall&#xe9;e A., LeCarpentier Y., Guillevin R., Vall&#xe9;e J.-N. Aerobic glycolysis in amyotrophic lateral sclerosis and Huntington&#x2019;s disease. Rev. Neurosci. 2018;29:547&#x2013;555. doi: 10.1515/revneuro-2017-0075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2017-0075</ArticleId><ArticleId IdType="pubmed">29303786</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonelli C., Chio I.I.C., Tuveson D.A. Transcriptional regulation by Nrf2. Antioxid. Redox Signal. 2018;29:1727&#x2013;1745. doi: 10.1089/ars.2017.7342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7342</ArticleId><ArticleId IdType="pmc">PMC6208165</ArticleId><ArticleId IdType="pubmed">28899199</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-S&#xe1;nchez S., Garc&#xed;a-Yag&#xfc;e &#xc1;.J., K&#xfc;gler S., Lastres-Becker I. CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies. Redox Biol. 2019;22:101118. doi: 10.1016/j.redox.2019.101118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2019.101118</ArticleId><ArticleId IdType="pmc">PMC6375000</ArticleId><ArticleId IdType="pubmed">30769286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Innamorato N.G., Jaworski T., R&#xe1;bano A., K&#xfc;gler S., Van Leuven F., Cuadrado A. Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain. 2013;137:78&#x2013;91. doi: 10.1093/brain/awt323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt323</ArticleId><ArticleId IdType="pubmed">24277722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Ulusoy A., Innamorato N.G., Sahin G., R&#xe1;bano A., Kirik D., Cuadrado A. &#x3b1;-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson&#x2019;s disease. Hum. Mol. Genet. 2012;21:3173&#x2013;3192. doi: 10.1093/hmg/dds143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds143</ArticleId><ArticleId IdType="pubmed">22513881</ArticleId></ArticleIdList></Reference><Reference><Citation>La Rosa P., Petrillo S., Turchi R., Berardinelli F., Schirinzi T., Vasco G., Lettieri-Barbato D., Fiorenza M.T., Bertini E.S., Aquilano K., et al. The Nrf2 induction prevents ferroptosis in Friedreich&#x2019;s Ataxia. Redox Biol. 2021;38:101791. doi: 10.1016/j.redox.2020.101791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101791</ArticleId><ArticleId IdType="pmc">PMC7677700</ArticleId><ArticleId IdType="pubmed">33197769</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A. NRF2 in neurodegenerative diseases. Curr. Opin. Toxicol. 2016;1:46&#x2013;53. doi: 10.1016/j.cotox.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cotox.2016.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlette A., Krampfl K., Grothe C., Von Neuhoff N., Dengler R., Petri S. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2008;67:1055&#x2013;1062. doi: 10.1097/NEN.0b013e31818b4906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818b4906</ArticleId><ArticleId IdType="pubmed">18957896</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., K&#xf6;rner S., Kiaei M. Nrf2/ARE signaling pathway: Key mediator in oxidative stress and potential therapeutic target in ALS. Neurol. Res. Int. 2012;2012:878030. doi: 10.1155/2012/878030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/878030</ArticleId><ArticleId IdType="pmc">PMC3461296</ArticleId><ArticleId IdType="pubmed">23050144</ArticleId></ArticleIdList></Reference><Reference><Citation>LoGerfo A., Chico L., Borgia L., Petrozzi L., Rocchi A., D&#x2019;Amelio A., Carlesi C., Caldarazzo Ienco E., Mancuso M., Siciliano G. Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients. Oxid. Med. Cell. Longev. 2014;2014:432626. doi: 10.1155/2014/432626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/432626</ArticleId><ArticleId IdType="pmc">PMC3941162</ArticleId><ArticleId IdType="pubmed">24672634</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo J.A., Zhang M., Yin F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front. Pharmacol. 2012;3:119. doi: 10.3389/fphar.2012.00119.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2012.00119</ArticleId><ArticleId IdType="pmc">PMC3400084</ArticleId><ArticleId IdType="pubmed">22833723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross D., Siegel D. NQO1 in protection against oxidative stress. Curr. Opin. Toxicol. 2018;7:67&#x2013;72. doi: 10.1016/j.cotox.2017.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cotox.2017.10.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Holmgren A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 2014;66:75&#x2013;87. doi: 10.1016/j.freeradbiomed.2013.07.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.07.036</ArticleId><ArticleId IdType="pubmed">23899494</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicencio E., Beltr&#xe1;n S., Labrador L., Manque P., Nassif M., Woehlbier U. Implications of selective autophagy dysfunction for ALS pathology. Cells. 2020;9:381. doi: 10.3390/cells9020381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020381</ArticleId><ArticleId IdType="pmc">PMC7072226</ArticleId><ArticleId IdType="pubmed">32046060</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans C.S., Holzbaur E.L. Autophagy and mitophagy in ALS. Neurobiol. Dis. 2019;122:35&#x2013;40. doi: 10.1016/j.nbd.2018.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.07.005</ArticleId><ArticleId IdType="pmc">PMC6366665</ArticleId><ArticleId IdType="pubmed">29981842</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusten T.E., Stenmark H. p62, an autophagy hero or culprit? Nat. Cell Biol. 2010;12:207&#x2013;209. doi: 10.1038/ncb0310-207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb0310-207</ArticleId><ArticleId IdType="pubmed">20190829</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo B.G., E Silva L.F.S., Torresi J.L.D.B., Siena A., Valerio B.C.O., Brito M.D., Rosenstock T.R. Decreased mitochondrial function, biogenesis, and degradation in peripheral blood mononuclear cells from amyotrophic lateral sclerosis patients as a potential tool for biomarker research. Mol. Neurobiol. 2020;57:5084&#x2013;5102. doi: 10.1007/s12035-020-02059-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02059-1</ArticleId><ArticleId IdType="pmc">PMC7541388</ArticleId><ArticleId IdType="pubmed">32840822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor&#xe1;n M., Delmiro A., Bl&#xe1;zquez A., Ugalde C., Arenas J., Mart&#xed;n M.A. Bulk autophagy, but not mitophagy, is increased in cellular model of mitochondrial disease. Biochim. Biophys. Acta Mol. Basis Dis. 2014;1842:1059&#x2013;1070. doi: 10.1016/j.bbadis.2014.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.03.013</ArticleId><ArticleId IdType="pubmed">24704045</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T., Tahara M., Todo S. The novel antioxidant Edaravone: From bench to bedside. Cardiovasc. Ther. 2008;26:101&#x2013;114. doi: 10.1111/j.1527-3466.2008.00041.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3466.2008.00041.x</ArticleId><ArticleId IdType="pubmed">18485133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang M.C., Kwak S.G., Park J.-S., Park D. The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis. Sci. Rep. 2020;10:1&#x2013;7. doi: 10.1038/s41598-020-71813-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-71813-1</ArticleId><ArticleId IdType="pmc">PMC7479139</ArticleId><ArticleId IdType="pubmed">32901053</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlstr&#xf6;m K.E., Ewing E., Granqvist M., Gyllenberg A., Aeinehband S., Enoksson S.L., Checa A., Badam T.V.S., Huang J., Gomez-Cabrero D., et al. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat. Commun. 2019;10:1&#x2013;13. doi: 10.1038/s41467-019-11139-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11139-3</ArticleId><ArticleId IdType="pmc">PMC6626021</ArticleId><ArticleId IdType="pubmed">31300673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Garcia-Yague A.J., Scannevin R.H., Casarejos M.J., Kugler S., Rabano A., Cuadrado A. Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson&#x2019;s Disease. Antioxid. Redox Signal. 2016;25:61&#x2013;77. doi: 10.1089/ars.2015.6549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2015.6549</ArticleId><ArticleId IdType="pmc">PMC4943471</ArticleId><ArticleId IdType="pubmed">27009601</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Ryder J., Mekhael L., Rd H., Mathers S., Needham M., Dw S., Mc K. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant) Medicine. 2020;99:e18904. doi: 10.1097/MD.0000000000018904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000018904</ArticleId><ArticleId IdType="pmc">PMC7015658</ArticleId><ArticleId IdType="pubmed">32028398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., D&#x2019;Amico R., Zucchi E., Gessani A., Fini N., Fasano A., Caponnetto C., Chi&#xf2; A., Dalla Bella E., Lunetta C., et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) Medicine. 2018;97:e11119. doi: 10.1097/MD.0000000000011119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de las Cuevas N., Munoz U., Bartolome F., Esteras N., Alquezar C., Martin-Requero A. Cell cycle and Alzheimer&#x2019;s disease: Studies in non-neuronal cells. J. Appl. Biomed. 2010;8:121&#x2013;130. doi: 10.2478/v10136-009-0015-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/v10136-009-0015-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia E., Limon D., Perez-De La Cruz V., Giordano M., Diaz-Mu&#xf1;oz M., Maldonado P.D., Herre-ra-Mundo M.N., Pedraza-Chaverri J., Santamaria A. Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: Protective role of S-allylcysteine. Free Radic. Res. 2008;42:892&#x2013;902. doi: 10.1080/10715760802506356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715760802506356</ArticleId><ArticleId IdType="pubmed">18985488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.-H., Sambol E.B., Kennealey P.T., O&#x2019;Connor R.B., DeCarolis P.L., Cory D.G., Singer S. Water suppression without signal loss in HR-MAS 1H NMR of cells and tissues. J. Magn. Reson. 2004;171:143&#x2013;150. doi: 10.1016/j.jmr.2004.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmr.2004.08.009</ArticleId><ArticleId IdType="pubmed">15504693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Kugler S., Lastres-Becker I. Pharmacological targeting of GSK-3 and NRF2 provides neuro-protection in a preclinical model of tauopathy. Redox Biol. 2018;14:522&#x2013;534. doi: 10.1016/j.redox.2017.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.10.010</ArticleId><ArticleId IdType="pmc">PMC5681345</ArticleId><ArticleId IdType="pubmed">29121589</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Mart&#xed;n-Moldes Z., Ye J., Lastres-Becker I. Transcription factors NRF2 and NF-&#x3ba;B are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. J. Biol. Chem. 2014;289:15244&#x2013;15258. doi: 10.1074/jbc.M113.540633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.540633</ArticleId><ArticleId IdType="pmc">PMC4140883</ArticleId><ArticleId IdType="pubmed">24759106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>